Why Cortexyme Thinks It Could Be Next In The Mega Alzheimer's Drug Market
Yahoo! Finance
The next donnybrook in Alzheimer's disease is looming. Biogen gained the first approval, and a slew of biotech stocks are now lining up.
Continue Reading